203 related articles for article (PubMed ID: 14593718)
21. Imidazo[1,2-b]pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors.
Byth KF; Cooper N; Culshaw JD; Heaton DW; Oakes SE; Minshull CA; Norman RA; Pauptit RA; Tucker JA; Breed J; Pannifer A; Rowsell S; Stanway JJ; Valentine AL; Thomas AP
Bioorg Med Chem Lett; 2004 May; 14(9):2249-52. PubMed ID: 15081018
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510: identification of 3' substituted indolones as a scaffold for the development of neuroprotective drugs.
Johnson K; Liu L; Majdzadeh N; Chavez C; Chin PC; Morrison B; Wang L; Park J; Chugh P; Chen HM; D'Mello SR
J Neurochem; 2005 May; 93(3):538-48. PubMed ID: 15836613
[TBL] [Abstract][Full Text] [Related]
23. A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different classes of novel Pfmrk specific inhibitors.
Bhattacharjee AK; Geyer JA; Woodard CL; Kathcart AK; Nichols DA; Prigge ST; Li Z; Mott BT; Waters NC
J Med Chem; 2004 Oct; 47(22):5418-26. PubMed ID: 15481979
[TBL] [Abstract][Full Text] [Related]
24. Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition.
Gussio R; Zaharevitz DW; McGrath CF; Pattabiraman N; Kellogg GE; Schultz C; Link A; Kunick C; Leost M; Meijer L; Sausville EA
Anticancer Drug Des; 2000 Feb; 15(1):53-66. PubMed ID: 10888036
[TBL] [Abstract][Full Text] [Related]
25. 3D-QSAR CoMFA study on indenopyrazole derivatives as cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 2 (CDK2) inhibitors.
Singh SK; Dessalew N; Bharatam PV
Eur J Med Chem; 2006 Nov; 41(11):1310-9. PubMed ID: 16890327
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of broad spectrum protein kinase inhibitors to probe the architecture of the malarial cyclin dependent protein kinase Pfmrk.
Woodard CL; Keenan SM; Gerena L; Welsh WJ; Geyer JA; Waters NC
Bioorg Med Chem Lett; 2007 Sep; 17(17):4961-6. PubMed ID: 17588749
[TBL] [Abstract][Full Text] [Related]
27. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
Thomas MP; McInnes C
IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
[TBL] [Abstract][Full Text] [Related]
28. Targeting malaria with specific CDK inhibitors.
Geyer JA; Prigge ST; Waters NC
Biochim Biophys Acta; 2005 Dec; 1754(1-2):160-70. PubMed ID: 16185941
[TBL] [Abstract][Full Text] [Related]
29. CDKs and CKIs: molecular targets for tissue remodelling.
Nabel EG
Nat Rev Drug Discov; 2002 Aug; 1(8):587-98. PubMed ID: 12402499
[TBL] [Abstract][Full Text] [Related]
30. [Prevention of chemotherapy-induced alopecia by cyclin-dependant kinase inhibitors].
Meijer L; Knockaert M; Damiens E
Bull Cancer; 2001 Apr; 88(4):347-50. PubMed ID: 11371368
[TBL] [Abstract][Full Text] [Related]
31. Small molecules as inhibitors of cyclin-dependent kinases.
Huwe A; Mazitschek R; Giannis A
Angew Chem Int Ed Engl; 2003 May; 42(19):2122-38. PubMed ID: 12761741
[TBL] [Abstract][Full Text] [Related]
32. Biochemical and cellular mechanisms of mammalian CDK inhibitors: a few unresolved issues.
Pei XH; Xiong Y
Oncogene; 2005 Apr; 24(17):2787-95. PubMed ID: 15838515
[TBL] [Abstract][Full Text] [Related]
33. Cyclin-dependent kinase inhibitors: a survey of recent patent literature.
Galons H; Oumata N; Meijer L
Expert Opin Ther Pat; 2010 Mar; 20(3):377-404. PubMed ID: 20180621
[TBL] [Abstract][Full Text] [Related]
34. Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design.
Kontopidis G; McInnes C; Pandalaneni SR; McNae I; Gibson D; Mezna M; Thomas M; Wood G; Wang S; Walkinshaw MD; Fischer PM
Chem Biol; 2006 Feb; 13(2):201-11. PubMed ID: 16492568
[TBL] [Abstract][Full Text] [Related]
35. Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors.
Anderson M; Andrews DM; Barker AJ; Brassington CA; Breed J; Byth KF; Culshaw JD; Finlay MR; Fisher E; McMiken HH; Green CP; Heaton DW; Nash IA; Newcombe NJ; Oakes SE; Pauptit RA; Roberts A; Stanway JJ; Thomas AP; Tucker JA; Walker M; Weir HM
Bioorg Med Chem Lett; 2008 Oct; 18(20):5487-92. PubMed ID: 18815031
[TBL] [Abstract][Full Text] [Related]
36. Imidazo[1,2-a]pyridines. Part 2: SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors.
Byth KF; Culshaw JD; Green S; Oakes SE; Thomas AP
Bioorg Med Chem Lett; 2004 May; 14(9):2245-8. PubMed ID: 15081017
[TBL] [Abstract][Full Text] [Related]
37. Identifying in vivo targets of cyclin-dependent kinase inhibitors by affinity chromatography.
Knockaert M; Meijer L
Biochem Pharmacol; 2002 Sep; 64(5-6):819-25. PubMed ID: 12213575
[TBL] [Abstract][Full Text] [Related]
38. Identification of novel BRAF kinase inhibitors with structure-based virtual screening.
Park H; Choi H; Hong S; Hong S
Bioorg Med Chem Lett; 2011 Oct; 21(19):5753-6. PubMed ID: 21873050
[TBL] [Abstract][Full Text] [Related]
39. A liquid chromatography/mass spectrometry-based method for the selection of ATP competitive kinase inhibitors.
Khandekar SS; Feng B; Yi T; Chen S; Laping N; Bramson N
J Biomol Screen; 2005 Aug; 10(5):447-55. PubMed ID: 16093554
[TBL] [Abstract][Full Text] [Related]
40. Selectivity and potency of cyclin-dependent kinase inhibitors.
Sridhar J; Akula N; Pattabiraman N
AAPS J; 2006 Mar; 8(1):E204-21. PubMed ID: 16584130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
